RVMD stock forecast, quote, news & analysis
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers... Show more
Revolution Medicines (RVMD) Stock Analysis: FDA NDA Acceptance Paves Path Toward First Commercial Launch
Key Takeaways
- Revolution Medicines shares traded near $187.53 as of late July 2026, reflecting a year-to-date gain of roughly 137% driven by pivotal clinical and regulatory milestones.
- The FDA accepted the company's New Drug Application (NDA) for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, triggering an accelerated review under the Commissioner's National Priority Voucher program.
- Phase 3 RASolute 302 data showed daraxonrasib nearly doubled median overall survival versus chemotherapy — 13.2 months compared to 6.7 months — marking a potential new standard of care in a high-unmet-need oncology setting.
- The company's RAS(ON) inhibitor platform spans four clinical-stage assets and eight ongoing or planned Phase 3 registrational trials across pancreatic, lung, and colorectal cancers.
- With approximately $4 billion in cash and financing proceeds and no approved products yet, the stock carries a market capitalization near $40 billion, pricing in substantial commercial execution ahead.
Current Market Snapshot
Revolution Medicines (RVMD) has been one of the standout biotechnology performers in 2026, with its share price more than doubling since the start of the year. After surging above $192 in late June on the heels of landmark clinical data and analyst upgrades, the stock consolidated around the $185–$190 range through July. The recent FDA acceptance of the daraxonrasib NDA provided further validation of the company's late-stage pipeline, though broader market volatility and profit-taking following the steep year-to-date rally have kept near-term price action range-bound. Institutional ownership remains near 94%, and the stock continues to attract significant attention from both growth-oriented biotech investors and major asset managers.
Revolution Medicines (RVMD) Business Overview and Competitive Position
Revolution Medicines is a late-stage clinical oncology company headquartered in Redwood City, California, focused on developing novel targeted therapies for RAS-addicted cancers. RAS proteins — historically labeled "undruggable" by the scientific community — play a central role in some of the most aggressive malignancies, including pancreatic, non-small cell lung, and colorectal cancers. The company's proprietary tri-complex inhibitor platform creates druggable binding sites on active RAS proteins, enabling its investigational drugs to block cancer cell signaling at the source.
The pipeline is anchored by daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor designed to target all three major RAS mutation hotspot positions. Additional clinical-stage assets include zoldonrasib (G12D-selective), elironrasib (G12C-selective), and RMC-5127 (G12V-selective). Revolution Medicines is also advancing next-generation catalytic RAS(ON) inhibitors, with RM-055 expected to enter first-in-human trials in late 2026. The company has established clinical collaborations with BMY, SMMT, and TNGX to evaluate combination regimens, further broadening its addressable market opportunity.
Recent Developments Driving RVMD
The most consequential recent catalyst was the FDA's acceptance of the daraxonrasib NDA, filed under the Commissioner's National Priority Voucher program, which compresses the standard review timeline significantly. This filing was supported by final overall survival and progression-free survival data from the Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in the risk of death compared with standard chemotherapy. The full results were presented at the 2026 ASCO Annual Meeting plenary session and published in The New England Journal of Medicine.
Additionally, the European Medicines Agency initiated an accelerated review procedure for daraxonrasib, positioning the company for a potential global launch. The company also announced a planned leadership transition: Steve Kelsey, president of research and development, will transition to senior advisor ahead of his retirement in January 2027, with an updated R&D leadership structure taking effect July 1, 2026.
On the financial front, Revolution Medicines reported a wider-than-expected first-quarter loss of $2.29 per share and raised its 2026 operating expense guidance to $1.7–$1.8 billion, reflecting increased investment in clinical trials and pre-commercial activities. The company completed financings totaling $2.2 billion in gross proceeds, bolstering its cash position for pipeline advancement. Meanwhile, billionaire investor Stanley Druckenmiller's Duquesne Family Office disclosed a 316,000-share position, and several Wall Street analysts — including Truist, Needham, and Wedbush — raised their price targets on the stock.
Trending AI Robots
For investors seeking systematic, data-driven approaches to navigate volatile markets like biotechnology, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI-powered trading bots. Tickeron hosts hundreds of automated trading bots that execute across thousands of tickers, but only the most consistent, high-performing strategies make it into the trending section. These bots span diverse methodologies — from swing trading and momentum-based approaches to longer-term trend-following systems — each with transparent performance metrics and track records. Traders can evaluate bots by strategy type, risk profile, and historical returns to find alignment with their own investment style. Exploring the Trending AI Robots section can help identify automated strategies currently resonating with market conditions.
2026 Outlook and What Investors Should Watch
The remainder of 2026 is poised to be transformative for Revolution Medicines. The FDA decision on daraxonrasib in second-line pancreatic cancer — expected within months under the accelerated review pathway — represents the single most important binary catalyst. An approval would transform the company into a commercial-stage entity and validate the broader RAS(ON) platform. Beyond the initial pancreatic cancer indication, investors should monitor enrollment progress in the RASolve 301 Phase 3 trial for daraxonrasib in non-small cell lung cancer, as well as the initiation of RASolute 309, a registrational trial evaluating the daraxonrasib-zoldonrasib doublet combination.
Clinical data readouts in colorectal cancer — where the company plans to share updated combination data later this year — could expand the addressable patient population. The Phase 2 dose identification for RMC-5127 (G12V-selective) and the initiation of first-in-human trials for RM-055 will provide important signals about the depth of the pipeline. On the financial side, investors should track cash burn rates against the company's $4 billion war chest, as well as any partnership or licensing developments that could alter the commercial or competitive landscape. Macroeconomic factors, including interest rate policy and sector rotation within healthcare, may also influence sentiment toward pre-revenue biotech names trading at premium valuations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RVMD's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for RVMD turned positive on August 06, 2026. Looking at past instances where RVMD's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on RVMD as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RVMD advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 260 cases where RVMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for RVMD moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
RVMD broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RVMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.892) is normal, around the industry mean (20.090). P/E Ratio (0.000) is within average values for comparable stocks, (25.983). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.649). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. RVMD's P/S Ratio (10000.000) is very high in comparison to the industry average of (464.478).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an oncology company, which focused on developing novel targeted therapies and engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment.
Industry Biotechnology